에서 실시간으로 운영 중이에요! 자세히 알아보기

Nuvation Bio

NUVB

시가총액 US$15.6억

4.45 USD

-0.30

6.32%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

4.46

+0.01

0.22%

1일

-6.32%

5일

-10.28%

1개월

-23.01%

3개월

-21.1%

6개월

-7.48%

연초 이후

-48.14%

1년

22.59%

5년

-52.91%

10년

-54.12%

소개: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

직원 수: 305

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 36.4%

중립 54.5%

부정적 9.1%

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months ahead of PDUFA date NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among patients who received IBTROZI after prior chemotherapy, response rates remained consistent, offering reassurance for patients who begin chemotherapy before a ROS1 fusion is identified NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating IBTROZI® (taletrectinib) in both TKI- naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

Zacks Investment Research

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.

Nuvation Bio to Participate in Upcoming Investor Conferences

Zacks Investment Research

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts

Nuvation Bio Inc. is downgraded to Hold after a >200% share price run, reflecting cautious optimism amid early Ibtrozi launch dynamics. Ibtrozi, now the leading ROS1 TKI in new patient starts, posted $23.2m Q2 revenues with strong first-line uptake, but overall patient starts declined sequentially. NUVB management projects a $3.8bn Ibtrozi peak revenue opportunity, but current sales and analyst estimates suggest a more modest trajectory near $650m.

Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA study enrollment underway NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1. "People with IDH1-mutant glioma urgently need additional treatment options.

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.